About TCM Life Science
TCM Life Science is TCM Biotech International's U.S. subsidiary for U101. The oral, non-antibiotic drug candidate is designed to prevent recurrent urinary tract infections.
TCM Biotech formed the Delaware subsidiary in May 2026 and licensed it global rights to U101 in July. The subsidiary plans to run U.S. clinical development and international commercialization.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 12, 2026 | Oct 26, 2026 | $16,666target not set | 2 | $8,333 | EquityRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed TCM Life Science
TCM Biotech created TCM Life Science to move U101 into U.S. development and global licensing. U101 uses an oral, non-antibiotic approach to prevent recurrent urinary tract infections. The parent company has completed an interim analysis in a Taiwan Phase III trial and is preparing a U.S. trial. It has also said it plans to raise a $55 million Series A for the subsidiary.
The problem it targets
Recurrent urinary tract infections are commonly prevented with antibiotics. Long-term use can promote bacterial resistance, while bladder instillations require a catheter. TCM Biotech says these limits leave a need for a convenient, non-antibiotic preventive treatment.
What the product does
U101 is an oral candidate that is intended to create a protective barrier on the urinary tract wall. TCM Biotech says the barrier can reduce bacterial adhesion and help repair urinary tissue. The parent licensed global clinical development, registration, manufacturing and commercialization rights to TCM Life Science.
Progress so far
TCM Biotech's Taiwan Phase III trial had enrolled more than 240 patients by October 2026, according to BigGo Finance. An independent monitoring committee found no safety reason to stop or redesign the trial at its interim analysis. The parent says the U.S. FDA will accept the Taiwan trial as one pivotal study, leaving one Phase III study for the United States.
Who backs it
TCM Biotech owns the subsidiary and supplied its U101 rights. In October 2026, management said it planned a $55 million Series A at a $550 million valuation, according to BigGo Finance. It expected the money to come mainly from existing TCM Biotech shareholders and to fund the U.S. Phase III trial.
We wrote this summary from public statements by TCM Life Science and its investors. It is not investment advice.
TCM Life Science in the News
- [TCM Biotech FY2026 Q3 Earnings Call] U101 U.S. Phase III Trial Launch Imminent; Subsidiary TCM Life Science Valued at $550 Million, Raising $55 Million in Series A
- 泰宗新藥獲239億授權金
- 【TCM Biotech FY2026 H1 Earnings Call】U101 Phase III Enrollment Surpasses 60%, Interim Analysis Looms in Q3; FDA Greenlights 505(b)(2) Pathway Saving Tens of Millions of Dollars; U.S. Subsidiary Established to Accelerate Global Licensing
Leadership Team
Executive officers and directors listed on TCM Life Science's Form D filed Oct 26, 2026.
